Actively Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Led by Vivace Therapeutics, Inc · Updated on 2026-04-02
434
Participants Needed
12
Research Sites
466 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
CONDITIONS
Official Title
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with metastatic or unresectable malignant mesothelioma who have not received systemic therapy (for combination cohort A and C)
- Patients with incurable locally advanced or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior Osimertinib treatment (for combination cohort B)
- Measurable disease per RECIST v1.1 or modified RECIST v1.1 for malignant pleural mesothelioma
- ECOG performance status of 0 or 1
- Adequate liver, kidney, and blood system functions
You will not qualify if you...
- Active brain metastases or primary central nervous system tumors
- History of leptomeningeal metastases
- Active or uncontrolled infections needing systemic therapy
- Known HIV positive or active Hepatitis B or C infection
- Clinically significant heart disease or prior exposure to cardiotoxic drugs
- Corrected QT interval greater than 470 msec
- Other active malignancies that could affect study results
- Pregnant or breastfeeding women
- Prior treatment with TEAD inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94158
Actively Recruiting
2
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
3
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
8
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
9
Virginia Cancer Specialists, PC
Arlington, Virginia, United States, 22201
Actively Recruiting
10
Monash Health
Clayton, Victoria, Australia, 3168
Actively Recruiting
11
Peter MacCullum Cancer Centre
Melbourne, Victoria, Australia, 3000
Actively Recruiting
12
Linear Clinical Research
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
Research Team
H
Heather Fritz
CONTACT
N
Neelesh Sharma, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here